Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
about
Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive TherapiesThe role of miR-29b in cancer: regulation, function, and signalingAberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic targetEpigenetics advancing personalized nanomedicine in cancer therapyUpdate on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunitiesDecitabine: a review of its use in older patients with acute myeloid leukaemia.Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway.Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.Clinical development of demethylating agents in hematologySmall molecule inhibitors in acute myeloid leukemia: from the bench to the clinicA subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitorImmunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma.Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemiaRational Combinations of Targeted Agents in AMLSelective activation of TNFR1 and NF-κB inhibition by a novel biyouyanagin analogue promotes apoptosis in acute leukemia cells.Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive TherapyPalbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapyClinical response to azacitidine therapy depends on microRNA-29c (miR-29c) expression in older acute myeloid leukemia (AML) patients.Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease.Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis.Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML).Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance.DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences.Emerging immunotherapies in older adults with acute myeloid leukemia.Proteasome inhibitors in acute leukemia.Epigenetics of myelodysplastic syndromes.Evolving treatment strategies in patients with high-risk acute myeloid leukemia.MicroRNAs expressed in hematopoietic stem/progenitor cells are deregulated in acute myeloid leukemias.miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.MicroRNAs in Myeloid Hematological Malignancies.
P2860
Q26772235-7EBF0523-BF87-453E-BB7D-D861FA277C12Q26851543-403AEEFA-41D2-4522-8CE7-F08B6AC4E339Q26995561-92D925A3-85B4-4578-B5E9-9125ED06F387Q27010637-E518D13A-8D6E-488A-97CE-61996C3F1B45Q28071384-D9846C33-B44F-47E5-A360-079C8AC9D30DQ33407030-0DDD587D-3B26-4BC7-B9B0-CE6B8EC12682Q34193684-457BBE19-16E2-4960-A4DC-26349BCCAE46Q34350209-4A421707-7E40-4958-BFD2-B8E5CBFDF564Q34395179-95E0F7CF-B39C-490E-9F47-4FEDC43098FBQ34817365-FA5E5322-77C4-4928-B4CE-80B60E72AF4AQ35176131-87A32F07-F184-453E-B4A8-DD6CCF8B0986Q35674158-D6D9D4A0-CFA7-4AC0-9113-D84E7F8E29F9Q35742564-D6382904-1305-4E93-8025-6636DB9F11C2Q35750491-DC41B496-9B5A-457F-AD47-70B7D300B857Q35995213-80C37E92-FCFE-48A8-92CB-8B515843AD9CQ36625210-2C6064A6-D2C1-493E-B09B-7EF5DC7F9ABFQ36848774-A60DA6DB-6362-4159-AD69-CC9CC6FBDF32Q37037268-01E908F2-6A67-4789-82A3-84467910248EQ37109858-9EC484A7-4B2A-4B58-BFC4-ADA1293800CCQ37233146-82D0968F-F49B-4762-B4A2-EE2946D0E2DFQ37327466-F7E6C61E-AD8B-4652-A9BA-D79EC5E8EB01Q37349410-EBA78042-0FB6-4E86-88C6-7181FCA86443Q37392719-125F3965-E694-45BA-8F2A-38D10EA16050Q37429089-360DC2C9-366C-4582-B0E6-4C7EE512221CQ37462852-D974CE90-9B95-4945-B1EC-7521C4E90E4BQ37587057-8B6A9362-1E7B-4B1A-9F44-754F06D14D6CQ37614613-68602264-A907-4C6D-9587-F095856B6342Q37643136-65872552-2E59-42F9-9060-159E0D1CAA8AQ37644854-5425B64C-361B-4816-9F53-0A63FC4C7224Q37679943-8B40FEB7-FEEA-41B5-ACA6-B8A169EA2ECAQ37723478-07431130-EDD4-481F-A214-60EAF3807808Q38040883-4CD98DF3-4C14-4C18-B136-8F166A76728FQ38075407-114ABE13-C61E-4C13-9118-D9EF92809B36Q38088003-E6700DA1-2140-4200-855F-0AF227375463Q38163846-90AB196B-9C21-4CAB-B53F-BA0CF8F45D56Q38179026-C81448DD-12E2-4497-BD26-DE7AA12D72B0Q38252974-7B85F85D-0CA6-422E-A228-0AE33E515C27Q38476564-69CDF437-AE44-4686-AB06-8D0D5DBC3D09Q38537883-FF78FAF0-841A-472B-9FBD-379235830E33Q38599595-9A48774A-D28C-4472-9FB0-EB73E3DE10DC
P2860
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Clinical and pharmacodynamic a ...... ine in acute myeloid leukemia.
@ast
Clinical and pharmacodynamic a ...... ine in acute myeloid leukemia.
@en
type
label
Clinical and pharmacodynamic a ...... ine in acute myeloid leukemia.
@ast
Clinical and pharmacodynamic a ...... ine in acute myeloid leukemia.
@en
prefLabel
Clinical and pharmacodynamic a ...... ine in acute myeloid leukemia.
@ast
Clinical and pharmacodynamic a ...... ine in acute myeloid leukemia.
@en
P2093
P2860
P50
P1433
P1476
Clinical and pharmacodynamic a ...... ine in acute myeloid leukemia.
@en
P2093
Alison Walker
Ann-Kathrin Eisfeld
Celia Garr
Cheryl Kefauver
Danilo Perrotti
Hongyan Wang
John P Curfman
Kenneth K Chan
Michael A Caligiuri
Michael R Grever
P2860
P304
P356
10.1182/BLOOD-2012-03-413898
P407
P577
2012-05-07T00:00:00Z